The Trump administration reached an agreement with Eli Lilly and Novo Nordisk to reduce U.S. prices for GLP‑1 weight‑loss drugs (some monthly costs near $250; future launches capped at $149). Many medicines will be offered to Medicaid at most‑favored‑nation prices. For the first time Medicare will cover GLP‑1s for obesity with an estimated $50 monthly copay for roughly 10% of beneficiaries (eligibility based on BMI and comorbidities), effective mid‑next year. A federal purchasing option called “TrumpRX” will allow direct consumer purchases. The companies pledged U.S. manufacturing investments and a CMS pilot could extend lower Medicaid access beginning in 2027; major insurers have not yet said if they will change coverage.

The agreement mandates large price reductions (some monthly costs near $250; future launches capped at $149) and new Medicare coverage with a low estimated $50 copay for eligible beneficiaries—measures that are likely to reduce revenue per unit. Offsetting factors noted are U.S. manufacturing pledges and potential expanded Medicaid access via a CMS pilot beginning in 2027. The facts in the summary therefore point to net negative commercial pricing pressure but with some operational commitments from the companies.